Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.56 |
| ▸ | TPSD1 | Q9BZJ3 | 4/20 | 0.56 |
| ▸ | TPSG1 | Q9NRR2 | 4/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638882 | 0.84 | TPSAB1 (0.56) | TPSAB1TPSD1TPSG1F2F10 | |
| SCHEMBL5637605 | 0.81 | FNTA (0.50) | F2ACEMME | |
| SCHEMBL5638998 | 0.79 | ACE (0.51) | TPSAB1TPSD1TPSG1F2F10 | |
| SCHEMBL5640435 | 0.78 | XIAP (0.41) | TPSAB1TPSD1TPSG1F10ACE | |
| SCHEMBL5638435 | 0.76 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1F10HTT | |
| SCHEMBL5638879 | 0.74 | TPSAB1 (0.37) | TPSAB1TPSD1TPSG1F2F10 | |
| SCHEMBL5637053 | 0.74 | ALDH1A1 (0.48) | F2F10ACEMMEHPGD | |
| SCHEMBL5638710 | 0.73 | MMP1 (0.54) | F2F10ACEMME | |
| SCHEMBL5638395 | 0.70 | CHRNB2 (0.47) | HTTLMNA | |
| SCHEMBL5638443 | 0.70 | TPSAB1 (0.37) | TPSAB1TPSD1TPSG1F10ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | TPSAB1 519/4885TPSD1 485/4885TPSG1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.